A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)

This open-label, randomized study will compare the efficacy and safety of the Bruton's
Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in subjects with Waldenström's
Macroglobulinemia who require therapy. Subjects will have baseline bone marrow samples
assayed for sequencing of the MYD88 gene. Approximately 188 subjects with the MYD88 mutation
will be enrolled onto Cohort 1 and randomized to receive 160 mg BGB-3111 PO BID (treatment
Arm A) or to receive 420mg ibrutinib QD (treatment Arm B) until disease progression or
unacceptable toxicity. Subjects with MYD88 wild type will be enrolled to Cohort 2 and will
receive 160 mg BGB-3111 PO BID (treatment Arm C) until disease progressive disease (PD) or
unacceptable toxicity, withdrawal of consent, loss to follow-up, or study termination by
Sponsor.

Inclusion Criteria:

- Clinical and definitive histologic diagnosis of WM

- Measurable disease, requiring treatment

- Patients with no prior therapy for WM, must be considered inappropriate candidates for
treatment with a standard chemoimmunotherapy regimen

- Age ≥ 18 years old

- (ECOG) performance status of 0-2

- Adequate bone marrow function

- Adequate renal and hepatic function

- ECHO/MUGA demonstrating left ventricular ejection fraction (LVEF)≥ the lower limit of
institutional normal

- Subjects may be enrolled who relapse after autologous stem cell transplant if they are
at least 3 months after transplant, and after allogeneic transplant if they are at
least 6 months post transplant.

- Females of childbearing potential must agree to use highly effective forms of birth
control throughout the course of the study and at least up to 90 days after last dose
of study drug. Males must have undergone sterilization- vasectomy, or utilize a
barrier method

- Life expectancy of > 4 months

Exclusion Criteria:

- Prior exposure to a BTK inhibitor

- Evidence of disease transformation at the time of study entry

- Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy given
with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or
antibody-based therapy within 4 weeks of the start of study drug

- Major surgery within 4 weeks of study treatment

- Toxicity of ≥ Grade 2 from prior anticancer therapy

- History of other active malignancies within 2 years of study entry, with exception of
(1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
with curative intent

- Currently active, clinically significant cardiovascular disease such as uncontrolled
arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease within 6 months
of screening

- QTcF prolongation (defined as a QTcF > 450 msec)

- Active, clinically significant Electrocardiogram (ECG) abnormalities

- Unable to swallow capsules or disease significantly affecting gastrointestinal
function such as malabsorption syndrome, resection of the stomach or small bowel,
symptomatic inflammatory bowel disease, or partial or complete bowel obstruction

- Uncontrolled active systemic infection or recent infection requiring parenteral
anti-microbial therapy

- Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C

- Pregnant or lactating women

- Any life-threatening illness, medical condition, organ system dysfunction, need for
profound anticoagulation, or bleeding disorder, which, in the investigator's opinion,
could compromise the subject's safety

- Any medications which are strong or moderate cytochrome P450, family 3, subfamily A
(CYP3A) inhibitors or strong CYP3A inducers